Update (9:37 a.m.): Updated with Tuesday market open information.
NEW YORK (TheStreet) -- Credit Suisse downgraded Allergan (AGN) to "neutral" from "outperform" and set a $190 price target. The firm noted risk/reward is balanced, following the latest bid from Valeant (VRX).
The stock was down 0.79% to $170.88 at 9:36 a.m. on Tuesday.
Must Read: Warren Buffett's 25 Favorite Stocks